MTC 896

Drug Profile

MTC 896

Alternative Names: MTC896

Latest Information Update: 05 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mimetica
  • Class Hormones; Skin disorder therapies
  • Mechanism of Action Melanocortin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acne vulgaris

Most Recent Events

  • 05 Dec 2017 Phase-II development for Acne vulgaris is ongoing in USA and Australia (Topical) (Mimetica website, December 2017)
  • 12 Jul 2017 Mimetica completes a phase II trial in Acne vulgaris (In volunteers) in Australia (Topical) (ACTRN12617000498392)
  • 03 May 2017 Phase-II clinical trials in Acne vulgaris (In volunteers) in Australia (Topical) (ACTRN12617000498392)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top